University of California, Los Angeles AIDS Prevention Treatment CTU

Site Details

LOCATION

9911 W. Pico Blvd.

Suite 980

Los Angeles, CA. 90035

Get Directions

SiteType

CTU

Site Trials

HIV Cure

Closed to accrual

A5386: IL-15 Superagonist (N-803) with and without Combination bnAbs

Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment (ART) is unable to reach. IL-15 superagonist (N-803) appears to reactivate HIV that is “asleep” and is also thought to increase the body’s natural immune response to HIV. Broadly neutralizing antibodies (bNAbs), such as 10-1074 and VRC07-523LS, have been shown to control growth of HIV in the blood and to increase the body’s immune response to HIV. N-803 alone or in combination with bNAbs may provide greater control of HIV than previous efforts.

COVID-19 and Mpox

Closed to accrual

A5418: Study of Tecovirimat for Human Mpox Virus

A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.